Daiwa Securities Group Inc. Ab Cellera Biologics Inc. Transaction History
Daiwa Securities Group Inc.
- $27.1 Billion
- Q2 2025
A detailed history of Daiwa Securities Group Inc. transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 1,151 shares of ABCL stock, worth $7,021. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,151
Previous 1,151
-0.0%
Holding current value
$7,021
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ABCL
# of Institutions
150Shares Held
114MCall Options Held
488KPut Options Held
476K-
Baker Bros. Advisors LP New York, NY27.5MShares$168 Million0.96% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$81.5 Million0.01% of portfolio
-
Baillie Gifford & CO10.4MShares$63.2 Million0.03% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL8.47MShares$51.7 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$27.7 Million0.02% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.74B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...